Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Oct 14

PMID 36233762

Authors

Shiori Sadaka

Takuji Iwashita

Hironori Fujii

Hiroko Kato-Hayashi

Koichi Ohata

Shinya Uemura

Masahito Shimizu

Akio Suzuki

Affiliations

Soon will be listed here.

Abstract

Aims: To evaluate the impact of first-line mFFX-induced PN on the efficacy of second-line GnP in patients with APC.

Methods: A database containing patients with APC was retrospectively analyzed to evaluate patients who received second-line GnP after first-line mFFX failure between September 2014 and January 2021. The efficacy and safety of GnP were compared between patients with PN ≥ Grade 2 (PN group) and PN ≤ Grade 1 (non-PN group) at the start of second-line GnP. Cox proportional hazards analysis was also performed to examine the effect on overall survival (OS) and time-to-treatment failure (TTF).

Results: Fifty-nine patients (PN group, 18 patients; non-PN group, 41 patients) were included. Median OS and TTF in the PN versus non-PN group were 7.7 versus 5.7 months ( = 0.19) and 3.8 versus 2.7 months ( = 0.18), respectively. Multivariate analysis showed that PN (≥Grade 2) was not a significant factor affecting either OS (hazard ratio (HR) 0.66, 95% confidence interval [CI] 0.33-1.31, = 0.24) or TTF (HR 0.71, 95% CI 0.38-1.33, = 0.28). No significant difference was observed in the relative dose intensity of GEM or nab-PTX, and incidence of adverse events.

Conclusions: mFFX-induced PN has little impact on the efficacy and safety of second-line GnP in patients with APC. Second-line GnP could be a possible treatment option regardless of the presence of PN.

Citing Articles

Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer.

Kawamoto Y, Yamai T, Ikezawa K, Seiki Y, Watsuji K, Hirao T BMC Cancer. 2024; 24(1):1000.

PMID: 39134950 PMC: 11321060. DOI: 10.1186/s12885-024-12722-8.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18(16):2938-47. DOI: 10.1200/JCO.2000.18.16.2938. View

Huh G, Lee H, Choi J, Lee S, Paik W, Ryu J . Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial. Ther Adv Med Oncol. 2021; 13:17588359211056179. PMC: 8591648. DOI: 10.1177/17588359211056179. View

Mizrahi J, Surana R, Valle J, Shroff R . Pancreatic cancer. Lancet. 2020; 395(10242):2008-2020. DOI: 10.1016/S0140-6736(20)30974-0. View

Ozaka M, Ishii H, Sato T, Ueno M, Ikeda M, Uesugi K . A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2018; 81(6):1017-1023. DOI: 10.1007/s00280-018-3577-9. View

Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S . The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer. Cancer Chemother Pharmacol. 2018; 82(4):625-633. DOI: 10.1007/s00280-018-3652-2. View

Mita N, Iwashita T, Uemura S, Yoshida K, Iwasa Y, Ando N . Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. J Clin Med. 2019; 8(6). PMC: 6616879. DOI: 10.3390/jcm8060761. View

Chae H, Jeong H, Cheon J, Chon H, Ryu H, Kim I . Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Ther Adv Med Oncol. 2020; 12:1758835920923424. PMC: 7257856. DOI: 10.1177/1758835920923424. View

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View

10.

Portal A, Pernot S, Tougeron D, Arbaud C, Thirot Bidault A, De La Fouchardiere C . Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015; 113(7):989-95. PMC: 4651133. DOI: 10.1038/bjc.2015.328. View

11.

Park S, Goldstein D, Krishnan A, Lin C, Friedlander M, Cassidy J . Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2014; 63(6):419-37. DOI: 10.3322/caac.21204. View

12.

Zhang Y, Hochster H, Stein S, Lacy J . Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol. 2015; 4:29. PMC: 4597390. DOI: 10.1186/s40164-015-0025-y. View

13.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K . Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17(12):1483-91. DOI: 10.1007/s00520-009-0613-7. View

14.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

15.

Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S . Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci. 2014; 105(10):1321-6. PMC: 4462360. DOI: 10.1111/cas.12501. View

16.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Nihei S, Sato J, Kashiwaba M, Itabashi T, Kudo K, Takahashi K . [Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy]. Gan To Kagaku Ryoho. 2013; 40(9):1189-93. View

19.

Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N . A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget. 2018; 8(67):111346-111355. PMC: 5762326. DOI: 10.18632/oncotarget.22795. View

20.

Smith E, Pang H, Cirrincione C, Fleishman S, Paskett E, Ahles T . Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13):1359-67. PMC: 3912515. DOI: 10.1001/jama.2013.2813. View